# Halozyme Therapeutics, Inc. (HALO) — Stock CV

Halozyme Therapeutics, Inc. is a $12.6B healthcare company. Revenue grew 41.2% over the last year, it keeps 25¢ of every dollar of sales as profit, and its net debt equals ~2.5 years of free cash flow. It trades at 30.3× earnings — near the highest of its own history.

> Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors.

## Identity

- **Ticker**: HALO
- **Sector**: Healthcare
- **Industry**: Biological Products, (No Diagnostic Substances)
- **Headquarters**: SAN DIEGO, CA
- **Employees**: 423
- **Website**: https://www.halozyme.com
- **Market cap**: $12.6B
- **Last price**: $111.35
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $1.66B
- **Net income**: $414M
- **Free cash flow**: $806M
- **Net debt**: $2.01B
- **P/E**: 30.3
- **Revenue growth (YoY)**: 41.2%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 44 |
| Growth | 75 |
| Profitability | 95 |
| Health | 50 |
| Quality | 65 |
| Moat | 48 |

## Qualifications (beginner checklist) — 9 of 10 passed

- [x] Revenue growing — +41.2% YoY
- [x] Profitable — $414M TTM
- [x] Profit growing — +21.2% YoY
- [x] Generates cash — $806M TTM
- [x] Debt under control — ~2.5y of cash flow to repay
- [x] Established company — $12.6B market cap
- [x] Not printing shares — -12.4% shares over ~5y
- [x] Proven track record — 7/10 profitable years
- [ ] Financially stable — health score 50/100
- [x] Valuation not extreme — P/E 30.3

## Experience (career milestones)

- **FY2024** — Revenue crossed $1B: $1.02B for the year
- **FY2024** — Best year on record: $444M net income
- **FY2020** — Positive free cash flow every year since: 6-year streak
- **FY2017** — Turned profitable: $63.0M net income after a loss year
- **FY2017** — Became debt-free: cash now exceeds total debt
- **1998** — The company was founded in 1998 and went public in 2004

## Strengths

- High gross margin (82.4%)
- Strongly profitable — 24.9% net margin
- Revenue growing 41.2% year over year
- Strong cash conversion — FCF is 48.5% of revenue
- Interest covered 143.5× by operating earnings

## Watch-outs

- Loss-making in 3 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $443M | $403M | $298M |
| FY2022 | $660M | $202M | $235M |
| FY2023 | $829M | $282M | $373M |
| FY2024 | $1.02B | $444M | $468M |
| FY2025 | $1.40B | $317M | $645M |

---

Source: https://stockcv.com/HALO — derived from company filings; may be delayed or incomplete. Information, not investment advice.